Sorrento up on completing enrollment in COVID treatment study

Sorrento Therapeutics

02/05/2022 15:43

** Shares of Sorrento Therapeutics  SRNE.O  rise 4.9% to
$1.58
    ** Co says early-stage study testing its intranasal
neutralizing antibody candidate, STI-9199, in healthy
volunteers, has been fully enrolled (https://refini.tv/39k92VR)
    ** STI-9199 has demonstrated in vitro and in vivo activity
against Omicron BA.2 variant, as well as all other SARS-CoV-2
variants of concern - SRNE
    ** Separate mid and late-stage studies in mild to moderate
COVID-19 patients is planned in U.S., China and Mexico for
Emergency Use Authorization submissions
    ** Stock down ~66% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))